Clinical research with methadone Ad libitum method in the treatment of cancer pain
Objective:To investigate the effectiveness and safety of methadone with Ad libitum(AL)method for the treatment of cancer pain.Methods:A total of 31 patients with inadequately controlled cancer pain,despite the use of high-dose opioid analgesics,were selected from the Pain Department of Jinling Hospital affiliated to Medical School of Nanjing University,from November 2022 to September 2023.As-needed oral methadone conversion was administered at 20 mg per dose(with an interval≥2 hours).Average pain numerical rating scale(NRS)scores were observed and recorded before and on day 1 to 7 and day 14 after methadone conversion.Adverse reactions were recorded before and on day 1,3,and 7 after conversion.Rescue frequencies were recorded from day 1 to 5 after conversion.Patient quality of life(QOL)was assessed before and on day 7 and 14 after conversion.Patient satisfaction and conversion success rate(NRS reduction≥50%,with no intolerable adverse reactions)were evaluated and calculated.Results:Compared to before conversion,average pain NRS scores were significantly reduced on day 1 to 7 and day 14 after conversion(P<0.05),and QOL was significantly improved(P<0.001).Rescue frequencies decreased with the extension of titration time.No intolerable adverse drug reactions occurred,and the overall satisfaction rate was 4.0(1.0),with a methadone conversion success rate of 93.5%.Conclusion:In patients using high-dose systemic opioid analgesics,oral methadone conversion at 20 mg per dose as needed showed clear effectiveness,minimal adverse reactions,improved patient quality of life,and high satisfaction rate.This approach is suitable for the Chinese population and can be considered for clinical use.
NETL
NSTL
万方数据
